PT  - JOURNAL ARTICLE
AU  - Alastair K Denniston
AU  - Usha Chakravarthy
AU  - Haogang Zhu
AU  - Aaron Y Lee
AU  - David P Crabb
AU  - Adnan Tufail
AU  - Clare Bailey
AU  - Toks Akerele
AU  - Sahar Al-Husainy
AU  - Christopher Brand
AU  - Louise Downey
AU  - Alan Fitt
AU  - Rehna Khan
AU  - Vineeth Kumar
AU  - Aires Lobo
AU  - Sajjad Mahmood
AU  - Kaveri Mandal
AU  - Martin Mckibbin
AU  - Geeta Menon
AU  - Salim Natha
AU  - Jong Min Ong
AU  - Marie D Tsaloumas
AU  - Atul Varma
AU  - Elizabeth Wilkinson
AU  - Robert L Johnston
AU  - Catherine A Egan
ED  - ,
TI  - The UK Diabetic Retinopathy Electronic Medical Record (UK DR EMR) Users Group, Report 2: real-world data for the impact of cataract surgery on diabetic macular oedema
AID  - 10.1136/bjophthalmol-2016-309838
DP  - 2017 Dec 01
TA  - British Journal of Ophthalmology
PG  - 1673--1678
VI  - 101
IP  - 12
4099  - http://bjo.bmj.com/content/101/12/1673.short
4100  - http://bjo.bmj.com/content/101/12/1673.full
SO  - Br J Ophthalmol2017 Dec 01; 101
AB  - Aim To assess the rate of ‘treatment-requiring diabetic macular oedema (DMO)’ in eyes for the two  years before and after cataract surgery.Methods Multicentre national diabetic retinopathy (DR) database study with anonymised data extraction across 19 centres from an electronic medical record system. Inclusion criteria: eyes undergoing cataract surgery in patients with diabetes with no history of DMO prior to study start. The minimum dataset included: age, visual acuity (all time-points), injection episodes, timing of cataract surgery and ETDRS grading of retinopathy and maculopathy. Main outcome measure: rate of developing first episode of treatment-requiring DMO in relation to timing of cataract surgery in the same eye.Results 4850 eyes met the inclusion criteria. The rate of developing treatment-requiring DMO in this cohort was 2.9% in the year prior to surgery versus 5.3% in the year after surgery (p<0.01). The risk of ‘treatment-requiring DMO’ increased sharply after surgery, peaking in the 3–6 months' period (annualised rates of 5.2%, 6.8%, 5.6% and 4.0% for the 0–3, 3–6, 6–9 and 9–12 months' post-operative time periods respectively). Risk was associated with pre-operative grade of retinopathy: risk of DMO in the first year post-operatively being 1.0% (no DR pre-operatively), 5.4% (mild non-proliferative diabetic retinopathy; NPDR), 10.0% (moderate NPDR), 13.1% (severe NPDR) and 4.9% (PDR) (p<0.01).Conclusions This large real-world study demonstrates that the rate of developing treatment-requiring DMO increases sharply in the year after cataract surgery for all grades of retinopathy, peaking in the 3–6 months' postoperative period. Patients with moderate and severe NPDR are at particularly high risk.